Page 4 - Serum Institute Of India

Govt allows SII to export 5 cr doses of Covid vaccine Covovax to Indonesia

The government has permitted export of 5 crore doses of Covovax, a Covid-19 vaccine domestically produced here by the Serum Institute of India

SC to hear plea seeking disclosure of data on Covid shots' trials on Nov 29

The apex court had earlier in August asked the Centre, Bharat Biotech, SII, and others to respond to the plea which sought directions to also disclose post-vaccination data regarding adverse events

Novavax files for emergency use listing of Covid-19 vaccine with WHO

Biotechnology firm Novavax Inc said it has completed the rolling submission for the emergency use listing (EUL) of its COVID-19 vaccine candidate to the World Health Organization (WHO). Earlier on Monday, Novavax and its partner Serum Institute of India (SII) had said that they had received the first emergency use authorisation (EUA) for COVID-19 vaccine in Indonesia. "The company has now completed the submission to World Health Organization (WHO) of all modules required for the regulatory evaluation of NVX-CoV2373, the company's recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant," Novavax Inc said in a statement on Thursday. The chemistry, manufacturing and controls module submitted to WHO, as well as other regulatory agencies worldwide, leverages Novavax' manufacturing partnership with the SII, the world's largest vaccine manufacturer by volume, it added. Novavax will make further submissions to enable vaccine supply from additional manufacturing sites

Novavax, SII get emergency use authorisation for Covid vaccine in Indonesia

The vaccine will be manufactured by SII in India and marketed by it in Indonesia under the brand name Covovax, Novavax Inc said in a statement

SII seeks regular marketing authorisation from DCGI for Covishield

If the DCGI grants regular marketing authorisation, Covishied will be the second vaccine in the world to receive such approval

Vaccine working on new variants next challenge: SII CEO Adar Poonawalla

'We are delivering 220 million doses a month, and almost everything is being consumed', said Poonawalla

Australia drugs regulator approves Covishield for incoming travelers

It is not immediately clear whether the TGA's approval for Covishield will facilitate immediate travel to Australia by Indian students waiting to return to that country

Australia drugs regulator approves India-made AstraZeneca vaccine for Covid

China-made vaccine recognised as well as Australia starts to unwind some of the world's most intense pandemic border restrictions.

Serum Institute gets nod to start Covovax trials on children above 7 yrs

Co has already started trials on 12-year-olds and above; trials will start phase wise in children; Poonawalla has said by Jan-Feb trial data may be ready to seek approval

Top headlines: Sebi clears gold exchange framework; NCLT relief for Future

Business Standard brings you the top headlines on Tuesday

DCGI allows Serum to enrol 7-11 year olds in Covid vaccine trial

So far, only drugmaker Zydus Cadila's DNA Covid vaccine has received emergency use approval in India to be used in adults and children aged 12 years and above

Novavax, SII apply to WHO for emergency use listing of Covid vaccine

Novavax Inc and its partner Serum Institute of India on Thursday said they have submitted an application to the World Health Organization for emergency use listing (EUL) of Novavax's COVID-19 vaccine.

SII to supply nearly 220 mn doses of Covishield vaccine to Centre in Oct

The Serum Institute of India has informed the Centre that it will be able to supply around 22 crore doses of Covishield in October

Time is right: Why India still has 12-16 weeks between Covishield doses

Difference between the effectiveness of a single dose versus two doses is not that large for protection from hospitalisation and severe disease.

India to resume export of Covid vaccines from October: Mansukh Mandaviya

Sources say the Centre has been working to create a stockpile of vaccines for India in case a third wave strikes

Centre orders 660 mn Covishield doses, to be supplied by Dec: Report

The Union government has placed a purchase order with the Serum Institute of India (SII) for 66 crore doses of Covishield to be supplied by December, official sources said on Thursday. The development comes after Prakash Kumar Singh, the Director, Government and Regulatory Affairs at SII, informed the Union Health Ministry that the firm would be able to supply 20.29 crore doses of Covishied in the month of September. The Pune-based firm has enhanced the manufacturing capacity of Covishield to more than 20 crore doses per month. The Health Ministry had in July placed an order with Bharat Biotech for the supply of 28.50 crore doses of Covaxin, but the firm has not been able to start the supply of those yet, an official source said. Bharat Biotech is close to completing the supply of five crore doses of Covaxin for which the Health Ministry had placed an order on March 12, the source said. The source added that the ministry had placed an order for 37.50 crore doses of Covishield betw

Allow second Covishield dose after 4 weeks from first: Kerala HC to Centre

The Kerala High Court has directed the Centre to allow scheduling, on CoWIN portal, of second COVISHIELD dose after four weeks from the first for those who want to take it earlier

Kerala HC allows Covishield second jab after 28 days in pvt sector

In a crucial intervention, the Kerala High Court on Monday ruled that the second dose of Covishield can be taken 28 days of taking the first dose in the private sector

India's coronavirus vaccine supply jumps, raising hopes of export

After donating or selling 66 million doses to nearly 100 countries, India barred exports in the middle of April to focus on domestic immunisation as infections exploded

No plan yet to revise Covishield 84-day dose gap, clarifies govt

Earlier there were reports that government could make a move to reduce the minimum gap between two doses of the Covishield Covid-19 vaccine, but NTAGI has denied the reports